UK markets closed

Zealand Pharma A/S (0NZU.L)

LSE - LSE Delayed price. Currency in DKK
Add to watchlist
126.80+8.08 (+6.81%)
At close: 05:30PM BST
Full screen
Previous close118.72
Open123.20
BidN/A x N/A
AskN/A x N/A
Day's range123.20 - 124.50
52-week range123.20 - 124.50
Volume11,884
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.67
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Total number of shares and voting rights in Zealand Pharma at March 31, 2024

    Company announcement – No. 21 / 2024 Total number of shares and voting rights in Zealand Pharma at March 31, 2024 Copenhagen, Denmark, March 31, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a calenda

  • GlobeNewswire

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

    Company announcement – No. 20 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securiti

  • GlobeNewswire

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

    Company announcement – No. 19 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 26, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 32,808 divided into 32,808 new shares with a nominal value of DKK 1 each. The incre